Abstract
ZL-1201 is a novel anti-CD47 antibody that has improved hematologic safety profiles and combines with SoC, including mAbs and chemotherapies, to potently facilitate phagocytosis and antitumor efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have